An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1)
AN OBSERVATIONAL STUDY OF AVASTIN® (BEVACIZUMAB) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER
1 other identifier
observational
300
1 country
30
Brief Summary
This multicenter, prospective, observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with chemotherapy as first-line treatment in patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in routine clinical practice. Eligible patients will be followed for approximately 15 months.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2013
Longer than P75 for all trials
30 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 10, 2013
CompletedFirst Submitted
Initial submission to the registry
May 23, 2013
CompletedFirst Posted
Study publicly available on registry
May 29, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 15, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
June 15, 2018
CompletedSeptember 17, 2018
September 1, 2018
5.1 years
May 23, 2013
September 13, 2018
Conditions
Outcome Measures
Primary Outcomes (2)
Progression-free survival, defined as time from first administration of first-line therapy to documented disease progression
approximately 6 years
Safety: Incidence of adverse events
approximately 6 years
Secondary Outcomes (5)
Overall survival, defined as time from first administration of first-line therapy to documented death
approximately 6 years
Objective response rate, defined as percentage of patients with complete or partial response according to local assessments
approximately 6 years
Quality of life: EQ-5D/EORTC questionnaires
approximately 6 years
Dosage/schedule/duration of Avastin therapy
approximately 6 years
Composition of first-line chemotherapy regimens: drugs/dosage/duration
approximately 6 years
Study Arms (1)
Cohort
Eligibility Criteria
Patients with advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer undergoing first-line treatment with chemotherapy and Avastin
You may qualify if:
- Adult patients, \>/= 18 years of age
- Advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube or primary peritoneal cancer not previously treated with chemotherapy
- Initiating Avastin in combination with chemotherapy
You may not qualify if:
- Contraindications, warnings and precautions for use as specified in the Avastin Summary of Product Characteristics
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (30)
Royal United Hospital; Oncology Department
Bath, BA1 3NG, United Kingdom
City Hospital
Birmingham, B18 7QH, United Kingdom
Bradford Royal Infirmary; Oncology Department
Bradford, BD9 6RJ, United Kingdom
Bristol Haematology and Oncology Centre
Bristol, BS2 8ED, United Kingdom
Queen's Hospital; Oncology Department
Burton-on-Trent, DE13 0RB, United Kingdom
Essex County Hospital
Colchester, CO3 3NB, United Kingdom
Eastborne District General Hospital
Eastbourne, BN21 2UD, United Kingdom
Wonford Hospital; Oncology Department
Exeter, EX2 5DW, United Kingdom
Royal Surrey County Hospital
Guildford, GU2 7XX, United Kingdom
Ipswich Hospital
Ipswich, IP4 5PD, United Kingdom
Airedale General Hospital; Research Office Ward 12
Keighley, BD20 6TD, United Kingdom
St James University Hospital
Leeds, LS9 7TF, United Kingdom
Royal Marsden Hospital - London
London, SW3 6JJ, United Kingdom
Maidstone Hospital; Kent Oncology Centre
Maidstone, ME16 0FS, United Kingdom
Christie Hospital Nhs Trust; Medical Oncology
Manchester, M2O 4BX, United Kingdom
The Clatterbridge Cancer Centre NHS Foundation Trust
Metropolitan Borough of Wirral, L63 4JY, United Kingdom
The James Cook University Hospital
Middlesbrough, TS4 3BW, United Kingdom
Mount Vernon Hospital
Middlesex, HA6 2RN, United Kingdom
St Mary's Hospital
Newport, PO30 5TG, United Kingdom
City Campus; Academic Unit of Oncology
Nottingham, NG5 1PB, United Kingdom
Queen Alexandra Hospital; Portsmouth Haematology & Oncology Centre, Level B
Portsmouth, PO6 3LY, United Kingdom
Weston Park Hospital; Cancer Clinical Trials Centre
Sheffield, S10 2SJ, United Kingdom
Southampton General Hospital
Southampton, SO16 6YD, United Kingdom
City General Hospital
Stoke-on-Trent, ST4 6QG, United Kingdom
The Royal Marsden Hospital
Sutton, SM2 5PT, United Kingdom
Singleton Hospital; Oncology
Swansea, SA2 8QA, United Kingdom
Torbay Hospital; Oncology Department
Torquay, TQ27AA, United Kingdom
Royal Cornwall Hospital
Truro, TR1 3LQ, United Kingdom
New Cross Hospital; Deansley Centre
Wolverhampton, WV10 0QP, United Kingdom
The York Hospital
York, YO31 8HE, United Kingdom
Related Publications (1)
Hall M, Bertelli G, Li L, Green C, Chan S, Yeoh CC, Hasan J, Jones R, Ograbek A, Perren TJ. Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study. Int J Gynecol Cancer. 2020 Feb;30(2):213-220. doi: 10.1136/ijgc-2019-000512. Epub 2019 Nov 27.
PMID: 31780570DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Clinical Trials
Hoffmann-La Roche
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 23, 2013
First Posted
May 29, 2013
Study Start
May 10, 2013
Primary Completion
June 15, 2018
Study Completion
June 15, 2018
Last Updated
September 17, 2018
Record last verified: 2018-09